398 related articles for article (PubMed ID: 19491669)
41. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
42. Update on recent developments for patients with newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
[TBL] [Abstract][Full Text] [Related]
43. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
[TBL] [Abstract][Full Text] [Related]
44. Autologous stem cell transplantation beyond 60 years of age.
Jantunen E
Bone Marrow Transplant; 2006 Dec; 38(11):715-20. PubMed ID: 17041609
[TBL] [Abstract][Full Text] [Related]
45. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
Moreau P; Avet-Loiseau H; Harousseau JL; Attal M
J Clin Oncol; 2011 May; 29(14):1898-906. PubMed ID: 21482979
[TBL] [Abstract][Full Text] [Related]
46. [Management of multiple myeloma].
Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
[TBL] [Abstract][Full Text] [Related]
47. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
48. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
49. Tandem autologous stem cell transplantation for multiple myeloma: is it applicable and effective outside clinical trials?
Dimopoulos MA
Haematologica; 2005 Dec; 90(12):1588. PubMed ID: 16330425
[No Abstract] [Full Text] [Related]
50. [Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma].
Sunami K
Rinsho Ketsueki; 2012 Jun; 53(6):580-6. PubMed ID: 22790632
[No Abstract] [Full Text] [Related]
51. Role of autologous bone marrow transplant in multiple myeloma.
Blanes M; de la Rubia J
Curr Opin Oncol; 2012 Nov; 24(6):733-41. PubMed ID: 23079784
[TBL] [Abstract][Full Text] [Related]
52. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
[TBL] [Abstract][Full Text] [Related]
53. Fundamentals in the management of multiple myeloma.
Fadilah SA
Med J Malaysia; 2010 Sep; 65(3):231-9. PubMed ID: 21939177
[TBL] [Abstract][Full Text] [Related]
54. Modern treatment options for elderly patients with multiple myeloma.
Görner M; Späth-Schwalbe E;
Onkologie; 2008 Jun; 31(6):335-42. PubMed ID: 18547977
[TBL] [Abstract][Full Text] [Related]
55. Current status of autologous hematopoietic stem cell transplantation in myeloma.
Mehta J; Singhal S
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
[TBL] [Abstract][Full Text] [Related]
56. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F; Harousseau JL; Mohty M
Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
[TBL] [Abstract][Full Text] [Related]
57. [Induction therapy of transplant-eligible patients in multiple myeloma].
Konishi J; Sunami K
Nihon Rinsho; 2015 Jan; 73(1):90-4. PubMed ID: 25626311
[TBL] [Abstract][Full Text] [Related]
58. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
[TBL] [Abstract][Full Text] [Related]
59. An update: health economics of managing multiple myeloma.
Moeremans K; Annemans L
Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
[TBL] [Abstract][Full Text] [Related]
60. Treatment options and considerations for the newly diagnosed myeloma patient.
Rajkumar VS;
Oncology (Williston Park); 2005 Sep; 19(10):1260, 1262, 1267 passim. PubMed ID: 16285223
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
